股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 FF301 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 260,295,700 | | 0 | | 260,295,700 | 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [5]. Core Insights - The company reported a revenue of 1.168 billion yuan for H1 2025, representing a year-on-year growth of 48.64%. The net loss was 413 million yuan, a reduction in loss of 36.01% compared to the previous year [1]. - The sales revenue of the company's core product, Tislelizumab, in the domestic market reached approximately 954 million yuan in H1 2025, showing a year-on-year increase of about 42%. The product has received approval for 12 indications, with four new indications added to the medical insurance directory in 2025 [2]. - The PD-1/VEGF dual antibody, JS207, is currently in Phase II clinical trials, demonstrating strong anti-tumor activity in preclinical studies. It is being explored in various tumor types in combination with other therapies [3]. - The company has a rich pipeline of oncology drugs, with the anti-BTLA monoclonal antibody, Tifcemalimab (JS004), currently in Phase III clinical trials for LS-SCLC, having enrolled nearly 400 patients [4]. Financial Summary - The company's revenue projections for 2025 and 2026 have been revised down to 2.584 billion yuan and 3.441 billion yuan, respectively. The expected net loss for 2025 is adjusted to 675 million yuan [5]. - The company’s total market capitalization is approximately 31.77 billion yuan, with a total share capital of 766.39 million shares [6]. - The earnings per share (EPS) is projected to improve from -2.32 yuan in 2023 to 0.18 yuan in 2027, indicating a potential turnaround in profitability [9].

FF301 截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 上海君實生物醫藥科技股份有限公司 呈交日期: 2025年10月8日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01877 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 260,295,700 | RMB | | 1 | RMB | | 260,295,700 | 第 2 ...

智通财经APP获悉，医药股再度强势，截至发稿，三叶草生物-B(02197)涨20.26%，报2.73港元；歌礼制 药-B(01672)涨15.05%，报11.47港元；康宁杰瑞制药-B(09966)涨11.02%，报15.21港元；药明合联 (02268)涨6.96%，报83.75港元；君实生物(01877)涨6.7%，报32.5港元。 消息面上，9月26日，美国总统特朗普宣布，从2025年10月1日起，将对任何品牌或专利的医药产品征收 100%的关税，除非公司正在美国建立他们的制药工厂。西南证券判断，预计该行政命令落地存在不确 定性。对中国创新药企而言，预计有直接创新药出口无美国建厂且对美国市场依赖度高的企业短期承 压；其余通过BD出海企业受影响较小，以License-out为例，其本质是知识产权交易，不涉及实体药品 出口，因此该政策对中国药企影响有限。中邮证券也表示，关税实际影响小，下跌为创新药加仓良机。 兴业证券指出，从创新药板块催化剂角度，进入10月将迎来ESMO（（10月17日-10月21日），此外12 月还有ASH（美国血液学学会）、圣安东尼奥乳腺癌大会等行业会议。另一方面，今年的对外授权交易 持 ...

备注：持股数变动有可能因供股、合股、拆股等情况引起，请注意对照实际情况进行辨别。 | 股票名称 | 机构名称 | 性质 | 变动前持股 | 变动后持股 | 持股比 | | --- | --- | --- | --- | --- | --- | | 龙记集团(00255) | 邵玉龙 | 好仓 | 4.07 亿股 | 4.14 亿股 | 65.52%(最新) 64.49%(前次) | | 龙记集团(00255) | 邵铁龙 | 好仓 | 4.07 亿股 | 4.14 亿股 | 65.52%(最新) 64.49%(前次) | | 敏实集团(00425) | 魏清莲 | 好仓 | 4.51 亿股 | 4.51 亿股 | 38.35%(最新) 38.34%(前次) | | 建滔积层板 (01888) | 叶澍堃 | 好仓 | 135.00 万股 | 115.00 万股 | 0.03%(最新) 0.04%(前次) | | 君实生物(01877) | 李鑫 | 好仓 | 8.29 万股 | 128.29 万股 | 0.49%(最新) 0.04%(前次) | | 博尼控股(01906) | Hong Kong Jun He ...

Core Insights - Junshi Biosciences experienced a slight increase in stock price by 0.22% on September 29, with a trading volume of 531 million yuan [1] - The company reported a net financing outflow of 599.84 million yuan on the same day, indicating a higher level of financing activity compared to the past year [1][2] - As of June 30, 2025, Junshi Biosciences achieved a revenue of 1.168 billion yuan, marking a year-on-year growth of 48.64% [2] Financing and Margin Trading - On September 29, Junshi Biosciences had a financing buy-in amount of 44.49 million yuan, with a total financing balance of 13.99 billion yuan, representing 4.44% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] - The company also had a margin trading balance of 599.84 million yuan, which is above the 60th percentile of the past year [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Junshi Biosciences increased to 31,200, a rise of 5.88% from the previous period [2] - The average number of circulating shares per shareholder decreased by 5.56% to 24,543 shares [2] - Major institutional shareholders include Huaxia SSE STAR 50 ETF and E Fund SSE STAR 50 ETF, with varying changes in their holdings [3]

Group 1 - The company has elected Ms. Li Xin as the employee representative director for the fourth board of directors, with her term starting from the approval date of the election and lasting until the end of the board's term [1][2][4] - Ms. Li Xin was previously a non-employee representative director and her election ensures that the number of directors who are also senior management or employee representatives does not exceed half of the total number of directors [2][5] Group 2 - The company held its first extraordinary general meeting of shareholders on September 29, 2025, where all proposed resolutions were approved without any being rejected [8][10] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with all 14 current directors and 3 supervisors present [9][22] Group 3 - The company approved the adjustment of its 2025 A-share stock option incentive plan, reducing the number of initial grant recipients from 251 to 235 and the total number of stock options from 25.36 million to 25.15 million [23][39] - The stock options will be granted at a price of 46.67 yuan per share, with the total number of options granted representing approximately 2.45% of the company's total share capital [35][42] Group 4 - The company conducted a self-examination regarding insider trading related to the stock option incentive plan, confirming that no insider information was leaked and that all trading activities were based on public market information [18][19][58] - The company has established a comprehensive approval process for the stock option incentive plan, ensuring compliance with relevant laws and regulations [61][62]

SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1877） 調整激勵對象名單及擬授予數量 及根據2025年A股股票期權計劃 向激勵對象首次授予A股股票期權 茲提述上海君實生物醫藥科技股份有限公司（「本公司」）日期為2025年9月2日的 公告及日期為2025年9月5日的通函（「該通函」），內容有關（其中包括）本公司 2025年A股股票期權激勵計劃及建議向熊先生授予。除非文義另有所指，否則本 公告所用詞彙與該通函所界定者具有相同涵義。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 調整首次授予A股股票期權之激勵對象名單及擬授予數量 由於16名激勵對象因離職失去激勵資格或因其他原因自願放棄激勵資格，董事會 及薪酬與考核委員會已決議根據股東於臨時股東大會的授權，對2025年A股股票 期權激勵計劃首次授予激勵對象名單、授予數量進行了調整。本 ...

智通财经APP讯，君实生物(01877)公布，公司控股子公司上海君拓生物医药科技有限公司(以下简称"君 拓生物")及其他投资方拟与北京沙砾生物医药股份有限公司(以下简称"北京沙砾"或"标的公司")、标的 公司创始人及相关方签订《增资协议》等交易文件，君拓生物拟以人民币8000 万元认购北京沙砾 1,280,623 股股份，本次增资完成后，公司及君拓生物将合计持有北京沙砾5.1105%股权。 另外，直接持有公司 5%以上股份的股东上海檀英投资合伙企业(有限合伙)拟参与本次增资，以人民币 4000 万元认购北京沙砾640,311股股份。 公司看好标的公司的未来发展，本次关联交易系公司控股子公司与上海檀英等专业投资机构以同等价格 共同投资北京沙砾，将促进公司与同行业其他公司加强合作，充分利用行业内优质资源，符合公司长期 发展战略，不会影响公司正常的生产经营活动，预计不会对公司经营业绩产生重大不利影响，符合公司 及全体股东利益。 据悉，标的公司是一家专注于肿瘤免疫细胞治疗，以肿瘤浸润淋巴细胞(以下简称"TIL")药物为代表研 发管线的创新型医药公司，拥有国际领先的技术储备和产业资源，旨在打造开创性的实体瘤细胞药物， ...

Core Viewpoint - Junshi Biosciences (01877) is investing in Beijing Shali Bio-pharmaceutical Co., Ltd. through its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., by subscribing to shares worth RMB 80 million, acquiring a 5.1105% stake in the company [1][2] Group 1 - Junshi Biosciences' subsidiary plans to subscribe to 1,280,623 shares of Beijing Shali for RMB 80 million, while another shareholder, Shanghai Tanying Investment Partnership, will invest RMB 40 million for 640,311 shares [1] - Beijing Shali specializes in tumor immune cell therapy, focusing on tumor-infiltrating lymphocytes (TIL) and has developed the first TIL drug approved for clinical registration in China, GT101, which is currently in critical Phase II clinical trials [1] - The company has also completed dual IND submissions for its first membrane-bound IL-15 complex TIL product, GT201, which is approved to enter Phase I clinical trials [1] Group 2 - The investment is seen as a strategic move to enhance collaboration within the industry and leverage high-quality resources, aligning with the long-term development strategy of Junshi Biosciences [2] - The transaction is expected to have no significant adverse impact on the company's normal operations or financial performance, benefiting the company and all shareholders [2]